Treatment of severe refractory adult atopic dermatitis with ustekinumab
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Editor, A 21-year-old Caucasian woman presented in March 2003 with a longstanding history of atopic dermatitis (AD) in addition to allergic contact dermatitis that emerged in response to paraphenylenediamine and had been diagnosed one year earlier (Fig. 1). She had undergone topical treatment with corticosteroids and calcineurin inhibitors with little improvement in her condition. Over the next six years, the patient underwent various treatments such as intermittent cycles of oral cyclosporine (4 mg/kg/day), ultraviolet B narrowband therapy (three times weekly), oral prednisone (1 mg/kg/day), and subcutaneous efalizumab (0.7 mg/kg initially followed by 1 mg/kg). Generalized atopic eczema on the arms shows signs of itching and scratching In December 2009, the patient began treatment with ustekinumab administered in a single dose of 45 mg. Two weeks later, the patient reported a substantial clinical improvement in her condition, especially in the pruritus. This improvement was rated on a 10-point visual analog scale (VAS). The VAS value before treatment was 9. One month later, the lesions had cleared and only hyperpigmented residual lesions presented on physical examination. The VAS value of pruritus was 0. A second 45-mg dose was administered at that point, according to the recommended dosage in psoriasis (at weeks 0 and 4, followed by every 12 weeks). The patient has currently completed month 12 of treatment. Her condition remains improved and pruritus is absent (Fig. 2). The eczema and pruritus are completely controlled after 12 months of continuous treatment Patients with AD often require systemic immunomodulatory and immunosuppressive agents (cyclosporine, azathioprine, methotrexate, and mycofenolate mofetil), but the use of these agents is limited by their potential toxicity and inadequate patient responses. Ustekinumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that binds with high specificity to the p40 subunit of interleukin-12 (IL-12) and IL-23. These immunoregulators are thought to play a role in immune-mediated inflammatory diseases. IL-12 is a heterodimer, consisting of p40 and p35 subunits. The IL-12 p40 subunit is shared by IL-23, another heterodimeric cytokine. IL-23 promotes the development and proliferation of T cells producing IL-17 (Th17). IL-12 has the capacity to regulate the differentiation of naive T cells into Th1 cells and the differentiation of CD8+ T cells into mature cytotoxic T lymphocytes. The exact etiology of AD is not completely understood. It was originally thought to result from a pathological Th2 immune response in the acute phase, with a switch toward a Th1 phenotype during the chronic phase.1 Classically, immunological theories have relied on the presence of two separate Th cell pathways of inflammation: Th1 (cell-mediated) and Th2 (humoral). Recent studies have provided evidence for a third effector CD4+ Th pathway, separate from Th1 to Th2. These T cells have been designated Th17. Naive T cells are polarized to Th17 cells in the presence of transforming growth factor-β1 (TGF-β1), IL-6, and IL-23. IL-23 is produced by antigen-presenting cells and promotes the expansion and survival of Th17.2 Th17-associated cytokines, IL-17 and IL-22, have many proinflammatory effects in a wide variety of cells, including keratinocytes, macrophages, and endothelial cells. IL-17 is highly expressed in autoimmune disorders such as Crohn's disease, multiple sclerosis, AD, psoriasis, and rheumatoid arthritis. The IL-17/IL-23 pathway appears to be involved in the maintenance of these chronic inflammatory diseases.3 In 2003, Toda et al.4 found elevated levels of IL-17 in acute lesions in AD. Koga et al.5 demonstrated that the percentage of Th17 cells was increased in peripheral blood of AD patients compared with a healthy group and was associated with the severity of AD. Immunohistochemistry of skin lesions demonstrated a higher percentage of Th17 cells in acute than in chronic lesions. These data suggest the participation of Th17 cells in the development of AD. The presence of Th17 cells in AD and psoriasis suggests the existence of a common pathway in the development of both inflammatory disorders. The binding between ustekinumab and IL-23 prevents the upregulation of Th17 cells. Therefore, ustekinumab may represent a good therapeutic option not only in psoriasis but also in AD. Our patient with longstanding AD showed a striking improvement after one month of ustekinumab therapy. The onset of action began in the first week of treatment, and the excellent response was maintained at week 52. In summary, we report the first case of the successful management of refractory AD in an adult with a new biologic therapy, ustekinumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New insights into atopic dermatitis
Leung, D. Y. M., Boguniewicz, M., Howell, M. D., Nomura, I., & Hamid, Q. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21060 · Cited by 1,435
Cited by
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
Werfel, T., Allam, J.-P., Biedermann, T., Eyerich, K., Gilles, S., Guttman-Yassky, E., Hoetzenecker, W., Knol, E., Simon, H.-U., Wollenberg, A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.010 · Cited by 594
Immunology of atopic eczema: overcoming the Th1/Th2 paradigm
Eyerich, K., & Novak, N. (2013) · Allergy · doi:10.1111/all.12184 · Cited by 325
Ghosh, D., Ding, L., Sivaprasad, U., Geh, E., Biagini Myers, J., Bernstein, J. A., Khurana Hershey, G. K., & Mersha, T. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0144316 · Cited by 94
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
Tan, H.-T. T., Sugita, K., & Akdis, C. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0650-5 · Cited by 68
Metadata
- Authors
- Puya, R., Alvarez‐López, M., Velez, A., Asuncion, E. C., & Moreno, J. C.
- Venue
- International Journal of Dermatology
- Publisher
- Wiley
- Published
- 2011-12-20
- Volume
- 51
- Issue
- 1
- Pages
- 115-116
- ISSN
- 0011-9059 (ISSN-L)
- 1365-4632
- OpenAlex
- W1571891468
- Cited by
- 73
- References
- 1
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of severe refractory adult atopic dermatitis with ustekinumab. https://app.cochat.ai/papers/10.1111/j.1365-4632.2011.05195.x
- The paper
- Puya, R., Alvarez‐López, M., Velez, A., Asuncion, E. C., & Moreno, J. C. (2012). Treatment of severe refractory adult atopic dermatitis with ustekinumab. International Journal of Dermatology. https://doi.org/10.1111/j.1365-4632.2011.05195.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.